Randolph M. Johnson, Ph.D.
Chief Development Officer
Dr. Johnson brings over 25 years experience in drug discovery to commercialization, having delivered Herceptin®, Aloxi®, together generating over $2 Billion in annual sales and a 3rd drug Parsabiv® expecting approval in 2017. Dr. Johnson has raised over $130 Million in capital funds, filed 11 INDs, is inventor on 12 U.S. and international patents and author of over 120 scientific publications, abstracts and book chapters. Previously he has held executive positions at Cortexyme , KAI Pharmaceuticals, Cellgate and DURECT Corp; was the head of Neurobiology and Molecular and Cellular Biochemistry at Roche and directed R&D at Syntex and Genentech. Dr. Johnson was Assistant Professor of Pharmacology at University of Virginia after receiving his Ph.D. in Biomedical Sciences-Pharmacology, from the University of South Carolina, and an M.A in Biology and B.S. in Zoology.